'en:gadofosveset'
(id=6890414 ; fe=en:gadofosveset ; type=1 ; niveau=200 ;
luminosité=25 ;
somme entrante=472 creation date=2017-06-25 touchdate=2024-09-18 20:34:28.000) ≈ 14 relations sortantes
- en:gadofosveset --
r_associated #0: 35 / 1 ->
en:gadobenic acid
n1=en:gadofosveset | n2=en:gadobenic acid | rel=r_associated | relid=0 | w=35
- en:gadofosveset --
r_associated #0: 24 / 0.686 ->
en:polysiloxane/gadolinium chelates-based nanoparticles
n1=en:gadofosveset | n2=en:polysiloxane/gadolinium chelates-based nanoparticles | rel=r_associated | relid=0 | w=24
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:carboxydextran-coated superparamagnetic iron oxide
n1=en:gadofosveset | n2=en:carboxydextran-coated superparamagnetic iron oxide | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:fda established names and unique ingredient identifier codes terminology
n1=en:gadofosveset | n2=en:fda established names and unique ingredient identifier codes terminology | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:gadofosveset trisodium anhydrous
n1=en:gadofosveset | n2=en:gadofosveset trisodium anhydrous | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:gadolinium-based contrast agent p03277
n1=en:gadofosveset | n2=en:gadolinium-based contrast agent p03277 | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:gadopenamide
n1=en:gadofosveset | n2=en:gadopenamide | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:gadopentetic acid
n1=en:gadofosveset | n2=en:gadopentetic acid | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:gadoxetic acid
n1=en:gadofosveset | n2=en:gadoxetic acid | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:gonorrheal urethral secretion human
n1=en:gadofosveset | n2=en:gonorrheal urethral secretion human | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:ionic gadolinium chelate
n1=en:gadofosveset | n2=en:ionic gadolinium chelate | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:iron ferrite
n1=en:gadofosveset | n2=en:iron ferrite | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:nonionic gadolinium chelate
n1=en:gadofosveset | n2=en:nonionic gadolinium chelate | rel=r_associated | relid=0 | w=20
- en:gadofosveset --
r_associated #0: 20 / 0.571 ->
en:nonionic macrocyclic gadolinium chelate
n1=en:gadofosveset | n2=en:nonionic macrocyclic gadolinium chelate | rel=r_associated | relid=0 | w=20
| ≈ 15 relations entrantes
- en:gadopenamide ---
r_associated #0: 42 -->
en:gadofosveset
n1=en:gadopenamide | n2=en:gadofosveset | rel=r_associated | relid=0 | w=42
- en:fda established names and unique ingredient identifier codes terminology ---
r_associated #0: 39 -->
en:gadofosveset
n1=en:fda established names and unique ingredient identifier codes terminology | n2=en:gadofosveset | rel=r_associated | relid=0 | w=39
- en:ionic gadolinium chelate ---
r_associated #0: 36 -->
en:gadofosveset
n1=en:ionic gadolinium chelate | n2=en:gadofosveset | rel=r_associated | relid=0 | w=36
- en:polysiloxane/gadolinium chelates-based nanoparticles ---
r_associated #0: 36 -->
en:gadofosveset
n1=en:polysiloxane/gadolinium chelates-based nanoparticles | n2=en:gadofosveset | rel=r_associated | relid=0 | w=36
- en:nonionic macrocyclic gadolinium chelate ---
r_associated #0: 34 -->
en:gadofosveset
n1=en:nonionic macrocyclic gadolinium chelate | n2=en:gadofosveset | rel=r_associated | relid=0 | w=34
- en:gadofosveset trisodium anhydrous ---
r_associated #0: 32 -->
en:gadofosveset
n1=en:gadofosveset trisodium anhydrous | n2=en:gadofosveset | rel=r_associated | relid=0 | w=32
- en:iron ferrite ---
r_associated #0: 31 -->
en:gadofosveset
n1=en:iron ferrite | n2=en:gadofosveset | rel=r_associated | relid=0 | w=31
- en:nonionic gadolinium chelate ---
r_associated #0: 31 -->
en:gadofosveset
n1=en:nonionic gadolinium chelate | n2=en:gadofosveset | rel=r_associated | relid=0 | w=31
- en:carboxydextran-coated superparamagnetic iron oxide ---
r_associated #0: 30 -->
en:gadofosveset
n1=en:carboxydextran-coated superparamagnetic iron oxide | n2=en:gadofosveset | rel=r_associated | relid=0 | w=30
- en:gadobenic acid ---
r_associated #0: 30 -->
en:gadofosveset
n1=en:gadobenic acid | n2=en:gadofosveset | rel=r_associated | relid=0 | w=30
- en:gonorrheal urethral secretion human ---
r_associated #0: 29 -->
en:gadofosveset
n1=en:gonorrheal urethral secretion human | n2=en:gadofosveset | rel=r_associated | relid=0 | w=29
- en:gadolinium-based contrast agent p03277 ---
r_associated #0: 27 -->
en:gadofosveset
n1=en:gadolinium-based contrast agent p03277 | n2=en:gadofosveset | rel=r_associated | relid=0 | w=27
- en:gadopentetic acid ---
r_associated #0: 27 -->
en:gadofosveset
n1=en:gadopentetic acid | n2=en:gadofosveset | rel=r_associated | relid=0 | w=27
- en:gadoxetic acid ---
r_associated #0: 27 -->
en:gadofosveset
n1=en:gadoxetic acid | n2=en:gadofosveset | rel=r_associated | relid=0 | w=27
- acide gadopentétique ---
r_associated #0: 21 -->
en:gadofosveset
n1=acide gadopentétique | n2=en:gadofosveset | rel=r_associated | relid=0 | w=21
|